TPG and Par plan $1.9bn wedding (unless a sugar daddy comes along)
This article was originally published in Scrip
Private investment firm TPG will pay $1.9 billion or $50 per share to acquire Par Pharmaceutical – a 37% premium over the generics manufacturer's 13 July stock price, unless Par can attract a stronger suitor within the next six weeks. The company's stock price shot up 36.7% to $50, a level unseen since early 2004.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.